Technology
SKYROCKETING INTO THE FUTURE: HOW DEHYDRATECH™ SUPERCHARGES YOUR NOVA EXPERIENCE
Step into the high-speed world of bio-delivery with NOVA's breakthrough technology. This is where science fiction meets reality. We're proud to feature Lexaria Bioscience’s patented DehydraTECH™ process - a game-changing Self-Emulsifying Delivery System (SEDS) that works like a well-orbiting satellite with cannabinoid molecules.
What if products actually went to work as soon as you took them? What if you were able to absorb almost all of the nutrients of that product? Or are we light years away from that kind of technology?! Indeed, we are not. NOVA’s products move at the speed of light. Not really, but the technology formulated into our masterpiece products would have you believe otherwise. We've got our foot on the pedal, making your body absorb nutrients faster and more effectively, ensuring our products kick into gear almost instantly.*
Lexaria Bioscience’s patented DehydraTECH™ process is a Self-Emulsifying Delivery System (SEDS). SEDS technologies are used in high-end bio-delivery processes and in NOVA’s case, they can be applied to cannabinoid molecules such as CBD. These methodologies are a scientifically-proven means of enhancing the bioavailability of poorly soluble substances, like CBD.* Simply put, DehydraTECH™ is how the cannabinoids (along with a ‘carrier’ agent) used in our products reach your bloodstream. The highly precise technology was developed to work with your body, so a galaxy of benefits comes tagging along.
Get ready to delve deep into how DehydraTECH™ functions, explore captivating charts and review numerous published studies and clinical trials. We're on the brink of an exhilarating adventure into the realm of high-end bio-delivery – a ride that promises to be extraordinarily nerdy, in the best possible way.
fact check
There are more highlights on DehydraTECH™ than there are on your aunt’s IG. But you’ll actually want to see these. In case you are wondering, there are no alternative facts here.
Benefits of DehydraTECH™ may include*:
- Increased bio-absorption (your body gets more): up to 10X versus other delivery methods*
- Reduced onset to just minutes from hours (feel it faster)*
- Up to 8x faster than standard delivery methods (lightning speed)*
- Masks unwanted tastes and smells (no ‘hemp’ bitterness or smell)*
- CBD is absorbed through the lymph system directly into your bloodstream to avoid liver degradation (it’s potent)*
- DehydraTECH avoids first-pass liver metabolism: the potency of the dose per serving does not experience the 75-85% reduction that typically occurs*
- Absorption is not diet-dependent: CBD enters your bloodstream directly through the thoracic duct via the lymphatic system (what you eat doesn’t matter – that’s your business)*
- Does not require “enhancing agents” to help the onset time or absorption rate (no additives)*
- Shelf life and potency are stable with testing currently at a 38-month shelf life (it’s not going anywhere)*
- Smaller doses yield exponentially higher results: higher absorption rates mean fewer milligrams needed per serving*
- Blood/brain barrier penetration is up to 246% greater than other CBD bio-delivery methods*
- Backed by both clinical studies and human clinical trials (the receipts are detailed below)*
- Robust intellectual property has 34 patents and roughly 50 pending worldwide (certified too legit to quit)*
As you might have surmised by now, DehydraTECH™ is rapidly becoming the leader in CBD and other active ingredient (APIs) delivery methods. How are all of these (potential) benefits possible? It seemed far out to us when we heard, but we phoned home and got the deets.
the process
LONG STORY SHORT:
A Cliff Notes version; it’s really very simple.
DehydraTECH™ envelopes the CBD molecule with a specific long-chain fatty acid (LCFA or LCT) and through a precise dehydration process combines it with a dissolvable powdered substrate (such as D-ribose used in Breakthrough). During that process, the CBD is plated or “locked” to the substrate allowing the substrate to carry the CBD into the body like a trojan horse, aka a ride share. Once the product is ingested, the LCT+CBD is released from the substrate and then acts as a chylomicron.* Chylomicrons are produced in the body’s small intestine and take certain molecules and lipids like CBD, to the bloodstream through the lymph system. Accordingly, the DehydraTECH™-infused CBD takes the same path as chylomicrons into your bloodstream.*
And, bam! A complete CBD molecule is in your bloodstream.* Super easy, right?
LONG STORY LONG:
A spiced-up medical journal version; it’s really very elegantly intricate.
Before the saga commences, know that this technology was designed to work naturally with your body, avoiding synthetics and other no-no’s in NOVA’s universe. DehydraTECH™ approaches solubility and absorption of CBD through already-occurring physiological processes, not processes created for solutions in a factory or a bottle. DehydraTECH™ works with, not counter to, the body’s eons-old systems of absorbing and processing nutrients. Bet.
DehydraTECH™ can be used on active ingredients (APIs) and cannabinoids – there are many possibilities. Currently, DehydraTECH™ is used on our products’ cannabinoids. It starts by encasing the cannabinoid molecule with a long-chain fatty acid, then attaching it to a substrate, or carrier, which then dissolves upon ingesting and leaves the cannabinoid molecule with the fatty acid to enter the body’s bloodstream. For today’s story time, Breakthrough will be used as an example to demonstrate exactly how not simple it really is.
Before broad-spectrum CBD distillate ever enters Breakthrough, it goes through a process that manifests its best self. DehydraTECH™ envelopes the CBD molecule with a specific long-chain fatty acid (LCFA or LCT). The molecular structure of the LCT used to coat the active molecule, in this case, CBD, is very similar to that of chylomicron naturally produced by the body. Chylomicrons are lipoproteins formed in the small intestine that transport dietary fats – fat-soluble molecules like CBD – through the lymphatic system directly to the bloodstream.
Chylomicrons are lipoprotein particles that are produced by the small intestine after the digestion and absorption of dietary fats. They are the largest and least dense lipoprotein particles and are composed of triglycerides, cholesterol, and other lipids, as well as apolipoproteins, which help to stabilize and transport the chylomicron in the bloodstream.
Once chylomicrons are synthesized in the small intestine, they enter the lymphatic system and eventually enter the bloodstream through the thoracic duct. In the bloodstream, they transport lipids (like the LCT used on NOVA’s products) to various tissues throughout the body, including adipose tissue, muscle, and the liver, where they are used for energy production or stored for later.
Chylomicrons have a short half-life in the bloodstream, typically only a few minutes, as they are rapidly cleared by the liver and other tissues. For Breakthrough, this means the CBD, brought in by the LCT, is quickly left unmetabolized on its own to do its thing in your bloodstream.*
After the CBD is coated with the LCT, it is plated or ‘locked’ to a substrate or carrier. Breakthrough’s substrate is D-ribose. Here, a substrate is the means by which the CBD is able to enter your body to be digested the way the technology intended. Typically, CBD is carried by MCT substrates.
NOVA’s scientists chose D-ribose for two reasons: it is naturally produced in the body, fueling your cells’ energy and it is a fully dissolvable ingredient. First, we wanted to ensure that every ingredient used in the formula had a purpose and a potential benefit, not just one or the other. Second, it is vital that the substrate be dissolvable (but still useful in the formulation) so that it can completely clear the fully intact LCT-enveloped CBD molecules. Those molecules must be ‘naked’ in order for them to function as chylomicrons, sliding into your bloodstream. D-ribose met both of those requirements.
One thing we didn’t have to consider was the particle size of D-ribose in the Breakthrough formula. DehydraTECH™ technology allows substrates to be of any size without impacting the size of the active molecule (CBD) once released. The active molecule (CBD) is encased in the specialized LCT; it is protected as the substrate dissolves and it is released at the ‘correct size’ for maximum absorption. So, in Breakthrough’s case, once the LCT-enveloped CBD is released by the D-ribose in the stomach, it becomes the appropriate size of the CBD molecule and is able to be transported to the lymph system unaltered.
After the D-ribose has dissolved, the LCT-coated CBD follows the same path and bio-delivery methods of lipids carried by chylomicrons (the molecule was released at the exact size needed to accomplish this). Absorption occurs through lacteal uptake via the thoracic duct in the lymph system. Once there, the LCT – because it is incredibly similar to chylomicrons – is disposed of quickly, leaving behind the CBD to flourish.*
The CBD thus enters the bloodstream in an unmetabolized form and is dispersed to appropriate receptors and tissues.* There is no first-pass liver metabolism which degrades the CBD up to 85% (and sometimes 95%) before it even enters your bloodstream like products without the tech.* DehydraTECH™ delivers a complete CBD molecule every time so dosing is precise and repeatable.* Every Breakthrough stick pack is the same as the next.
detailed check the facts
- Improves the way active ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods*
- Increases the effectiveness of fat-soluble active molecules (like LCT/CBD), thereby lowering overall dosing*
- Bio-delivery and absorption are not dependent on the amount of fat in the user’s diet because the CBD is enveloped within a specialized LCT*
- DehydraTECH™ “locks” the CBD to the substrate, so potency, stability and shelf life are exponentially increased*
- DehydraTECH™’s LCT is very similar to the body’s chylomicrons: The LCT-associated CBD molecule enters the bloodstream in minutes via the thoracic duct, into the lymphatic system and is sent directly to the peripheral tissues, mimicking chylomicrons and avoiding first-pass liver metabolism*
- Avoids the standard 75% to 85% CBD liver degradation that typically occurs with other delivery methods, thus, preserving the CBD’s bioavailability and indicated dosage*
Clinical and Scholarly Studies
Ready for the good stuff? Lexaria, the company that developed DehydraTECH™, has countless trials and studies published. However, we’re only going to look at the most pertinent to you: a trial and published study on DehydraTECH™ with CBD in the form of capsules.
Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study[2]
The degree and speed of CBD absorption into the blood plasma, as well as any potential cardiovascular and cognitive performance support, were studied.
TRIAL DESIGN:
- OBJECTIVES:
a. Investigate a joint pharmacokinetic-physiological time course of multiple recreational-equivalent (< 100 mg) dosages of oral CBD in young healthy adults.
b. Evaluate a newly developed technology (TurboCBD™ - Lexaria’s DehydraTECH™ CBD capsule) for the enhanced delivery of CBD. - METHODS:
a. Double-blinded, placebo-controlled, cross-over design.
b. 12 participants received a placebo, generic 45mg or 90 mg of CBD, or TurboCBD™ delivery technology capsules on five separate occasions.
c. Pharmacokinetic-based study: participants were monitored throughout the entire duration of the study. Pharmacokinetics (PK) is the study of how the body interacts with administered substances for the entire duration of exposure.
CBD ABSORPTION RESULTS:
- 30 Minutes: CBD delivered from Lexaria’s TurboCBD™ capsules was absorbed much more effectively than from the positive control, delivering 317% more CBD to blood at the 30-minute mark of the study (i.e., 18.4 ng/mL compared to only 4.4 ng/mL on average respectively [95% CI; p=0.051])*
- 60 Minutes: The TurboCBD™ capsules went on to deliver more CBD to the blood at the 60-minute mark (i.e., 38.8 ng/mL) than the positive control capsules were able to reach at any time during the 6-hour study, further demonstrating the exceptional rapidity of action and effectiveness of the TurboCBD™ capsules*
- 90 Minutes: The TurboCBD™ capsules further went on to deliver significantly more CBD to the blood (86% more) than the positive control capsules at the 90-minute mark (i.e., 53.0 ng/mL compared to only 28.4 ng/mL respectively [95% CI; p=0.034])
- Through to Study Completion: Lexaria’s TurboCBD™ capsules continued to deliver more CBD to blood than the positive control capsules at each subsequent time point in the study through to the 6-hour mark when the study was completed*
CARDIOVASCULAR AND COGNITIVE PERFORMANCE RESULTS:
According to the study: “A single 90mg dose of TurboCBD™ [DehydraTECH™] provided evidence of lower blood pressure; higher blood flow to the brain; faster delivery onset of CBD into the bloodstream; and, larger quantities of CBD within the blood compared to a single 90mg dose of generic CBD.”*
- Analysis of mean arterial blood pressure (MAP) at peak blood levels of CBD achieved with Lexaria’s TurboCBD™ demonstrated a significant reduction in MAP compared to placebo (95% CI; p=0.027). This finding was not observed with the dose-matched positive control formulation for which there was no significant decrease in MAP compared to placebo (95% CI; p=0.625) * [2]
a. Once the DehydraTECH™ CBD (TurboCBD™) reached its peak potency within the bloodstream, scientists observed a “significant reduction in MAP compared to” the group that did not receive any CBD.* [2] - Cerebral perfusion was also analyzed by an index of conductance in the middle cerebral artery (MCA). The findings revealed that Lexaria’s TurboCBD™ caused the greatest increase in MCA conductance relative to both the positive control formulation and placebo (95% CI; p=0.017 and P=0.002 respectively) * [2]
a. Oxygen was pushed faster and more efficiently to the brain tissue (blood-brain barrier penetration) in the group that took the DehydraTECH™ CBD (TurboCBD™) capsules.* [2] - Over the six-hour study, analysis of the total area under the curve (AUC) demonstrated that Lexaria’s TurboCBD™ resulted in a notable trend for higher levels of CBD in the bloodstream overall than the positive control formulation with total AUC of 10,865 ± 6,322 observed with Lexaria’s formulation compared to 7,115 ± 2,978 observed with the positive control (95% CI; p=0.096).* [2]
a. In the group that took the DehydraTECH™ CBD (TurboCBD™) capsules, higher levels of CBD were in their bloodstreams versus the positive control formulation. * [2] - In the group that took the DehydraTECH™ CBD (TurboCBD™) capsules, higher levels of CBD were in their bloodstreams versus the positive control formulation. * [2]
CITATIONS:
[2] Patrician A, Versic-Bratincevic M, Mijacika T, Banic I, Marendic M, Sutlović D, Dujić Ž, Ainslie PN. Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study. Adv Ther. 2019 Nov;36(11):3196-3210. doi: 10.1007/s12325-019-01074-6. Epub 2019 Sep 12. PMID: 31512143.